Ultrarapid urokinase in hemodialysis access occlusion.
Over a 3-month period, 14 consecutive hemodialysis access occlusions were treated with 1-1.25 million IU of urokinase (UK) delivered at a rate of 20,000 IU/min. After systemic heparin administration, lytic infusion via the crossed-catheter technique was performed with use of pediatric microdrip pumps, with determination of success within 1 hour. Patency was established radiographically in 11 of 14 occlusions, for a 79% immediate success rate. At 285-day mean follow-up, 9% (one of 11) remained patent without further radiologic or surgical intervention; graft survival was 64% (seven of 11). No significant complications occurred with use of ultrarapid UK. The 1-hour outpatient procedure safely allowed for rapid triage between surgical and radiologic intervention, minimal catheter manipulation or physician dependency, shorter duration compression of any bleeding venipuncture sites during UK administration, and greater patient comfort because of shortened procedure times.
Brunner
M C
MC
Department of Diagnostic Radiology and Nuclear Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612.
Matalon
T A
TA
Patel
S K
SK
McDonald
V
V
Jensik
S C
SC
D001166:Arteriovenous Shunt, Surgical; D006083:Graft Occlusion, Vascular / Q000188:drug therapy*; D006801:Humans; D006435:Renal Dialysis; D013997:Time Factors; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*
D014568:Urokinase-Type Plasminogen Activator